Back to search
FDAFDA · Food and drugs·Recall number D-1071-2020

Glycopyrrolate Tablets, USP 1 mg, 100-count bottle, Rx only, Dist. by: Par Pharmaceutical, Chestnut Ridge, NY, 10977, U.S.A, Mfg. by: Par Formulations Private Limited, 1/58, Pudupakkam, Kelambakkam - 603 103., Made in India NDC# 49884-0065-01

Published April 8, 2020 · Recall initiated: March 30, 2020

Summary

FDA records drug Class II recall D-1071-2020, published April 8, 2020 and initiated March 30, 2020. Recalling firm: Par Pharmaceutical Inc.; Status: Terminated; Reported quantity: 29,352 bottles; Lot: Lot # 32809101, Exp 3/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Par Pharmaceutical Inc.
Distributor
Product was distributed within the United States.
Lot
Lot # 32809101, Exp 3/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glycopyrrolate Tablets, USP 1 mg, 100-count bottle, Rx only, Dist. by: Par Pharmaceutical, Chestnut Ridge, NY, 10977, U.S.A, Mfg. by: Par Formulations Private Limited, 1/58, Pudupakkam, Kelambakkam - 603 103., Made in India NDC# 49884-0065-01 recalled?

Yes. FDA published recall D-1071-2020 on April 8, 2020. Reported hazard: Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

What should I do if I have this product?

Voluntary: Firm initiated · Letter